PharmaShots | Incisive News in 3 Shots

Subscribe Now

WW License Agreement

Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease

Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease

October 27, 2021

Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candidates

Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candi...

October 1, 2021

Seagen Signs an Exclusive WW License Agreement with RemeGen to Develop and Commercialize Disitamab Vedotin

Seagen Signs an Exclusive WW License Agreement with RemeGen to Develop and Commercialize Disitamab Vedotin

August 10, 2021

Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease

Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease

July 16, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us